| Drug General Information |
| Drug ID |
D0E5IP
|
| Former ID |
DIB020095
|
| Drug Name |
WHI-P154
|
| Synonyms |
WHI-P154; JAK inhibitors
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C16H14BrN3O3
|
| InChI |
InChI=1S/C16H14BrN3O3/c1-22-14-6-10-12(7-15(14)23-2)18-8-19-16(10)20-9-3-4-13(21)11(17)5-9/h3-8,21H,1-2H3,(H,18,19,20)
|
| InChIKey |
CBIAKDAYHRWZCU-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
4554808, 8152403, 14804325, 26758984, 29222914, 46391344, 53788345, 53800729, 57321998, 76533468, 85261794, 85267454, 99302708, 103594500, 104103316, 104304544, 121365196, 126407715, 127600149, 135698401, 137002695, 142433660, 162009763, 162974940, 163687863, 164194022, 175607416, 178102615, 179148633, 186000978, 204356796, 208264945, 210274995, 210280633, 225373246, 226416682, 241376268, 249776668, 251910577, 251971134, 252157028, 252448267, 252450640, 252553987
|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase JAK2 |
Target Info |
Inhibitor |
[2]
|
|---|
| Epidermal growth factor receptor |
Target Info |
Inhibitor |
[2]
|
| Tyrosine-protein kinase JAK3 |
Target Info |
Inhibitor |
[2]
|
| JAK1 |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
Chemokine signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Jak-STAT signaling pathway
|
|
Cholinergic synapse
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Leishmaniasis
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Measles
|
|
Influenza A
|
|
Herpes simplex infectionhsa04010:MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
Calcium signaling pathway
|
|
Cytokine-cytokine receptor interaction
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Endocytosis
|
|
Dorso-ventral axis formation
|
|
Focal adhesion
|
|
Adherens junction
|
|
Gap junction
|
|
Regulation of actin cytoskeleton
|
|
GnRH signaling pathway
|
|
Estrogen signaling pathway
|
|
Oxytocin signaling pathway
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Hepatitis C
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
MicroRNAs in cancer
|
|
Pancreatic cancer
|
|
Endometrial cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
Bladder cancer
|
|
Non-small cell lung cancer
|
|
Central carbon metabolism in cancer
|
|
Choline metabolism in cancerhsa04062:Chemokine signaling pathway
|
|
HTLV-I infection
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
Primary immunodeficiencyhsa04151:PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Hepatitis B
|
|
Herpes simplex infection
|
|
NetPath Pathway
|
IL4 Signaling Pathway
|
|
EGFR1 Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Inflammation mediated by chemokine and cytokine signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
JAK/STAT signaling pathway
|
|
PDGF signaling pathway
|
|
PI3 kinase pathway
|
|
CCKR signaling map STP00012:Cadherin signaling pathway
|
|
EGF receptor signaling pathwayP00036:Interleukin signaling pathway
|
|
PDGF signaling pathwayP00005:Angiogenesis
|
|
Pathway Interaction Database
|
Endothelins
|
|
ErbB4 signaling events
|
|
GMCSF-mediated signaling events
|
|
IL4-mediated signaling events
|
|
IL27-mediated signaling events
|
|
Signaling events mediated by PTP1B
|
|
IL12-mediated signaling events
|
|
S1P3 pathway
|
|
SHP2 signaling
|
|
CXCR4-mediated signaling events
|
|
IL5-mediated signaling events
|
|
IFN-gamma pathway
|
|
ErbB2/ErbB3 signaling events
|
|
IL3-mediated signaling events
|
|
IL6-mediated signaling events
|
|
PDGFR-beta signaling pathway
|
|
IL23-mediated signaling events
|
|
Signaling events mediated by Stem cell factor receptor (c-Kit)
|
|
EPO signaling pathway
|
|
Notch-mediated HES/HEY networklysophospholipid_pathway:LPA receptor mediated events
|
|
Arf6 signaling events
|
|
Signaling events mediated by TCPTP
|
|
Thromboxane A2 receptor signaling
|
|
Regulation of Telomerase
|
|
EGF receptor (ErbB1) signaling pathway
|
|
EGFR-dependent Endothelin signaling events
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Direct p53 effectors
|
|
ErbB1 downstream signaling
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
E-cadherin signaling in keratinocytes
|
|
ErbB receptor signaling network
|
|
Internalization of ErbB1
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
a6b1 and a6b4 Integrin signaling
|
|
Syndecan-3-mediated signaling eventsil4_2pathway:IL4-mediated signaling events
|
|
CD40/CD40L signaling
|
|
IL2-mediated signaling events
|
|
IL2 signaling events mediated by PI3K
|
|
IL2 signaling events mediated by STAT5p73pathway:p73 transcription factor network
|
|
PDGFR-alpha signaling pathway
|
|
IL2 signaling events mediated by STAT5
|
|
Reactome
|
Interleukin-6 signaling
|
|
MAPK3 (ERK1) activation
|
|
MAPK1 (ERK2) activation
|
|
GPVI-mediated activation cascade
|
|
Prolactin receptor signaling
|
|
RMTs methylate histone arginines
|
|
G beta:gamma signalling through PI3Kgamma
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
RAF activation
|
|
RAF/MAP kinase cascade
|
|
Interferon gamma signaling
|
|
Regulation of IFNG signaling
|
|
Interleukin receptor SHC signaling
|
|
Growth hormone receptor signaling
|
|
Factors involved in megakaryocyte development and platelet productionR-HSA-1236382:Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
|
|
SHC1 events in ERBB2 signaling
|
|
PLCG1 events in ERBB2 signaling
|
|
PIP3 activates AKT signaling
|
|
GRB2 events in EGFR signaling
|
|
GAB1 signalosome
|
|
SHC1 events in EGFR signaling
|
|
EGFR downregulation
|
|
GRB2 events in ERBB2 signaling
|
|
PI3K events in ERBB2 signaling
|
|
EGFR Transactivation by Gastrin
|
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
|
Constitutive Signaling by EGFRvIII
|
|
RAF/MAP kinase cascadeR-HSA-114604:GPVI-mediated activation cascade
|
|
Interleukin-7 signaling
|
|
Interleukin-2 signaling
|
|
Interleukin receptor SHC signalingR-HSA-1059683:Interleukin-6 signaling
|
|
ISG15 antiviral mechanism
|
|
Interferon alpha/beta signaling
|
|
Regulation of IFNA signaling
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Type II interferon signaling (IFNG)
|
|
Notch Signaling Pathway
|
|
EPO Receptor Signaling
|
|
EGF/EGFR Signaling Pathway
|
|
IL-4 Signaling Pathway
|
|
IL-6 signaling pathway
|
|
Kit receptor signaling pathway
|
|
IL-3 Signaling Pathway
|
|
Mesodermal Commitment Pathway
|
|
Interleukin-2 signaling
|
|
Signaling by SCF-KIT
|
|
Prolactin receptor signaling
|
|
Growth hormone receptor signaling
|
|
JAK/STAT
|
|
BDNF signaling pathway
|
|
Oncostatin M Signaling Pathway
|
|
Interleukin-11 Signaling Pathway
|
|
AGE/RAGE pathway
|
|
TSLP Signaling Pathway
|
|
IL17 signaling pathway
|
|
Leptin signaling pathway
|
|
TSH signaling pathway
|
|
Interleukin-3, 5 and GM-CSF signaling
|
|
Interferon gamma signaling
|
|
Factors involved in megakaryocyte development and platelet production
|
|
IL-5 Signaling PathwayWP673:ErbB Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
MAPK Signaling Pathway
|
|
Focal Adhesion
|
|
Aryl Hydrocarbon Receptor Pathway
|
|
Extracellular vesicle-mediated signaling in recipient cells
|
|
TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Bladder Cancer
|
|
Hair Follicle Development: Induction (Part 1 of 3)
|
|
Signaling by ERBB4
|
|
Signaling by ERBB2
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
PIP3 activates AKT signaling
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Aryl Hydrocarbon Receptor
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Gastric cancer network 2
|
|
Signaling Pathways in Glioblastoma
|
|
Arylhydrocarbon receptor (AhR) signaling pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
Integrated Breast Cancer Pathway
|
|
Signaling by EGFR
|
|
L1CAM interactionsWP49:IL-2 Signaling Pathway
|
|
Interleukin-7 signaling
|
|
IL-9 Signaling Pathway
|
|
IL-7 Signaling Pathway
|
|
Interleukin-3, 5 and GM-CSF signalingWP619:Type II interferon signaling (IFNG)
|
|
Interferon type I signaling pathways
|
|
TGF Beta Signaling Pathway
|
|
IL-2 Signaling Pathway
|
|
PDGF Pathway
|
|
Prostate Cancer
|
|
Type III interferon signaling
|
|
Integrated Cancer pathway
|
|
Interferon alpha/beta signaling
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5993). |
|---|
| REF 2 | The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. Epub 2007 Dec 19. |
|---|
